Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the BCMA directed therapies in multiple myeloma with a focus on Arcellx's lead product candidate, CART-ddBCMA

Ticker(s): ACLX

Who's the expert?

Institution: Harvard Medical School | Mass General

Clinical Director, Center for Multiple Myeloma, Mass General Cancer Center & Assistant Professor of Medicine Harvard Medical School.
Manages 350+ patients with multiple myeloma.
Principal investigator of several trials in relapsed multiple myelomas, including investigator-initiated trials.

Interview Goal

This conversation will focus on novel therapies in development for multiple myeloma with a focus on CART-ddBCMA, Arcellx's lead product candidate which, is being developed for the treatment of relapsed or refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.